# Phase II Clinical Study of AC591 in Preventing Oxaliplatin-Induced Peripheral Neuropathy

> **NCT06722950** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Shandong New Time Pharmaceutical Co., LTD** · enrollment: 120 (estimated)

## Conditions studied

- Colorectal Adenoma

## Interventions

- **DRUG:** CAPEOX
- **DRUG:** Placebo
- **DRUG:** AC591

## Key facts

- **NCT ID:** NCT06722950
- **Lead sponsor:** Shandong New Time Pharmaceutical Co., LTD
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-12
- **Primary completion:** 2026-12
- **Final completion:** 2026-12
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2024-12-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06722950

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06722950, "Phase II Clinical Study of AC591 in Preventing Oxaliplatin-Induced Peripheral Neuropathy". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT06722950. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*